← Leaderboards
Jean-Loup Romet-Lemonne
Traverse Biotech Ii Inc
$996,610
Attributed
$996,610
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $400K · FY2023–25$500K$375K$250K$125K$0
'23
'24
'25
Funding mix
By agency
NIH$996,610 · 2
By mechanism
R43$996,610 · 2
Top collaborators
No co-investigators on record.
Others in their field
Other Rising Stars on “Signal Transduction”
- Suma Babu · Massachusetts General Hospital$20,303,231
- Sabrina Paganoni · Massachusetts General Hospital$20,303,231
- Thomas K Karikari · Wake Forest University Health Sciences$12,972,426
- Gregory Sorenson · University Of Maryland Baltimore County$9,161,697
- Charles Daniel Meyers · Tempero Bio, Inc.$5,310,920
- Ian Gurrell · Astrazeneca Pharmaceuticals, Lp$5,256,914
Research focus
Signal TransductionIn VivoImmunotherapyPreclinical DevelopmentToxic EffectDoseFutureImmuneMouse ModelPre-ClinicalTherapeutic EffectTherapy DevelopmentTargeted TreatmentNovel TherapeuticsBindingBiotechnologyCellsCollaborationsIn VitroAssay DevelopmentAreaAmphotericin BAffectAmphotericin
Grant awards (3)
Orally available NOD2 agonist, HPX-612, for the treatment of visceral leishmaniasis$297,717
R43 · FY2025 · AI · contact PI
Orally available NOD2 agonist, HPX-612, for the treatment of visceral leishmaniasis$298,938
R43 · FY2024 · AI · contact PI
CD3 bispecific for the treatment of ROR2-positive NSCLC$399,955
R43 · FY2023 · CA · contact PI